Wyeth finds itself in the #12 spot of 15 for research and development budget with $2.35 bn EUR and #10 in overall sales for 2006.
2007 was a tough year for the company as its 3 big drug candidates, bifeprunox, an antipsychotic, HCV-796, a hepatitis C drug and Pristiq, a major depressive
disorder drug all received FDA non-approval or were delayed. Bifeprunox received a non-approval letter from the FDA, the clinical Phase II trial of HCV-796 was stopped due to adverse events in two patients and Pristiq’s launch was delayed because of an approvable letter. Wyeth also saw the voluntary recall of some Robitussin and Children's Dimetapp products and filed for FDA approval on Tygacil for community acquired pneumonia. Pending approval:
PhasePristiq - Major depressive disorder
Bifeprunox - schizophrenia
Lybrel - Continuous contraception
Viviant - Postmenopausal osteoporosis
Pristiq - Vasomotor symptoms of menopause
Torisel - Renal cell carcinomaIII [Source: FierceBiotech]
.jpg)
» 2007 Edition of the European Commission's Report of R&D Spending from PharmaGazette
The 2007 edition of the European Commission's annual report of research and development spending places Pfizer Inc. at the top of the heap outspending all other industries.Pharmaceuticals and biotechnology became the top R&D spenders beating ou... [Read More]
Tracked on: December 14, 2007 2:18 PM | Permalink to Trackback